EFTR Stock Performance, Insider Transaction and News

EFTR - eFFECTOR Therapeutics, Inc.

Market Cap	43.85M	P/E	-	EPS this Y	68.40%	Ern Qtrly Grth	-
Income	-35.81M	Forward P/E	-0.75	EPS next Y	60.70%	50D Avg Chg	-18.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	23.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	-	52W High Chg	-64.00%
Recommedations	1.50	Quick Ratio	0.71	Shares Outstanding	3.69M	52W Low Chg	110.00%
Insider Own	3.63%	ROA	-85.26%	Shares Float	3.38M	Beta	0.52
Inst Own	17.57%	ROE	-	Shares Shorted/Prior	345.20K/222.29K	Price	0.71
Gross Margin	-	Profit Margin	-	Avg. Volume	2,247,787	Target Price	11.00
Oper. Margin	-	Earnings Date	May 7	Volume	695,066	Change	-4.20%

Healthcare | Biotechnology | United States

About eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

eFFECTOR Therapeutics, Inc. News

04/09/24	eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
04/04/24	eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
03/25/24	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
02/05/24	eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/29/24	eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
01/25/24	eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
01/09/24	eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
01/09/24	eFFECTOR Therapeutics Announces Reverse Stock Split
12/08/23	eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
11/28/23	eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
11/15/23	eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
11/13/23	eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/06/23	eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
10/24/23	eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
08/30/23	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
08/11/23	eFFECTOR Therapeutics First Half 2023 Earnings: US$0.41 loss per share (vs US$0.093 loss in 1H 2022)
08/08/23	eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
06/08/23	eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
06/07/23	eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
05/31/23	eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

EFTR Chatroom

T2420 Posted - 11 hours ago

$EFTR what the HELL happened to this pos?

809capital Posted - 12 hours ago

$HOOK wrong. I always sell run ups to catalyst, I like when they shake the tree before news. Look at $EFTR. 🔥🔥💯💯

Rampton Posted - 13 hours ago

$EFTR I’ve just loaded another 7k at $1.77, as the next results get closer, this will be going up, big money to be made🚀🚀🚀🚀🚀

Rampton Posted - 13 hours ago

$EFTR Low stock float, just 3.5m shares, now at equivalent of 7c pre 25 to 1 stock split. $15m in the bank and just $6m market cap.🚀🚀🚀🚀💰💰💰💰

T2420 Posted - 13 hours ago

$EFTR zero? Not believable

dddanielek Posted - 16 hours ago

$EFTR bought more today on sale as far as I am concerned. This may be a longer hold but SP will most likely creep up as we get closer to next data release

Gunnar1 Posted - 17 hours ago

$XFOR $MCRB $SPRB $RVNC $EFTR Hopefully things are getting better next wek after OPEX tomorrow...

NikoST Posted - 18 hours ago

$EFTR 👀yoo

Rampton Posted - 1 day ago

$EFTR I’ve had top up today 1417 shares at $1.85, expecting to see a return of at least $10 before results. And if anyone is brave enough, could be 10x that on positive results.🚀🚀🚀💰💰💰💰💰💰💰💰💰💰

Rampton Posted - 1 day ago

$EFTR In the pipeline and External Collaborations eIF4Ei Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Solid Tumors Pfizer $507M deal value with option to co-promote and profit share

Rampton Posted - 1 day ago

$EFTR Other Cancer drugs in the pipeline, next results coming Q3 this year, this stock will only increase in the next 3 months as results get closer. With the right results, this is a $100 stock minimum. Life changing money to be made, dont forget this was a $16 stock a couple of weeks ago while waiting on results.🚀🚀🚀💰💰🚀

Rampton Posted - 1 day ago

$EFTR Current market cap of just $6m, money in bank $15m and fully funded until Q1 2025.

Rampton Posted - 1 day ago

$EFTR They raised $15m in cash just over 10 weeks ago at over $10 a share.

Rampton Posted - 1 day ago

$EFTR I am still super excited with this stock, equivalent of 7c pre reverse stock split of 25 to 1.

zawojak Posted - 1 day ago

@Mikko1238 similar to $EFTR also was promising and behaved similar way, look where it is now. All the very best

zawojak Posted - 2 days ago

@pumpersareidiotic delay will only mean one thing - trial has failed ! Like $EFTR

DavidChiaverini Posted - 2 days ago

$EFTR Adding some here for a bounce to $3

Kiwi17 Posted - 2 days ago

$EFTR how did conference go? I didn’t listen unfortunately.

Tshanky_ Posted - 2 days ago

$EFTR accumulating. Try to get my avg down to 2

RetiredGuy68 Posted - 2 days ago

$EFTR After my big loss I can see the logic of getting back in but the risk seems significant on many levels

Rollercoaster22 Posted - 2 days ago

$EFTR Conference starts in 15 minutes.

nUme22 Posted - 2 days ago

$MRNS $SPRB $EFTR $AMLX finally made some bucks with bargain hunting.. lol.

Kiwi17 Posted - 2 days ago

$EFTR presentation day!!!

Dustinash Posted - 3 days ago

@Short_Fisker unfortunately I sold half my shares yesterday at a loss becuase I wanted to get $EFTR and $DCFC .. both very interesting vastly oversold companies. Your question is good. And actually I would say that is absolutely the smartest way to play. Becuase you protect some profits even if this does declare bankruptcy.. this is a traders strategy and has been my intent. Had I not sold my shares yesterday I would have sold half today after 100% move up. But since I lightened my position if I were to sell now it would just not be worth losing the end game. So instead of trading I am now in for a swing. This is different and accepts volatility until target is reached or your stopped out. Because I view this as a 20 to 1 risk reward, I don’t have a stop. If it drops to a penny I’d add. If it declares bankruptcy I’ll try and exit on a dead cat bounce.

TheGrowthSensei Posted - 3 days ago

$EFTR with most the market falling thought may as well make the bag heavier and buy more

Kiwi17 Posted - 3 days ago

$EFTR tomorrow, they are speaking at 2024 Stifel Oncology Forum. Will we see some action?!

FeliciaMath Posted - 3 days ago

bought more $eftr at 1.88 today

Kikic Posted - 3 days ago

$EFTR where did all the pumpers go? You said it would go to $50 after great data 🤣

nUme22 Posted - 3 days ago

$MRNS buying here...although all recent bargain buys have been trashes.. $SPRB, $EFTR , $AMLX let's see .. if this one works or not.

LabPsycho Posted - 3 days ago

$EFTR IMO, could go below 1 again....then what? Many of the red flags opinions were apparent last Oct/Nov and posted here....where are my bashers?

Analyst Ratings

HC Wainwright & Co.	Buy	Mar 28, 24
HC Wainwright & Co.	Buy	Feb 6, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner 10% Owner	Nov 27	Sell	0.61	609,163	371,589	1,821,415	11/29/23
WORLAND STEPHEN T	Chief Executive Offi.. Chief Executive Officer	Aug 11	Option	0.52	33,799	17,575	261,225	08/14/23
Ehrlich Christopher B	Director Director	Oct 04	Buy	0.57	346	197	35,213	10/06/22
Ehrlich Christopher B	Director Director	Sep 26	Buy	0.55	18,867	10,377	34,867	09/27/22
Presidio Management Group X LL...	10% Owner 10% Owner	Aug 01	Sell	0.8	114,280	91,424	127,569	08/03/22
Presidio Management Group X LL...	10% Owner 10% Owner	Jul 28	Sell	0.89	32,517	28,940	131,025	07/29/22
Presidio Management Group X LL...	10% Owner 10% Owner	Jul 25	Sell	0.91	48,719	44,334	132,009	07/27/22
Presidio Management Group X LL...	10% Owner 10% Owner	Jul 20	Sell	0.96	20,309	19,497	133,483	07/22/22
Gallagher Brian M. Jr.	Director Director	Jun 23	Buy	1.59	30,000	47,700	30,000	06/27/22
WORLAND STEPHEN T	President and Chief.. President and Chief Executive	Jun 07	Buy	1.37	20,000	27,400	214,978	06/09/22
Byrnes Michael	Chief Financial Offi.. Chief Financial Officer	Jun 07	Buy	1.3305	25,000	33,262	29,233	06/07/22
Presidio Management Group X LL...	10% Owner 10% Owner	May 17	Sell	1.72	34,427	59,214	136,241	05/19/22
Presidio Management Group X LL...	10% Owner 10% Owner	May 12	Sell	1.86	46,176	85,887	137,309	05/16/22
Presidio Management Group X LL...	10% Owner 10% Owner	May 09	Sell	2.43	48,984	119,031	138,741	05/11/22
Ehrlich Christopher B	Director Director	Feb 08	Buy	4.84	2,000	9,680	13,000	02/10/22
Ehrlich Christopher B	Director Director	Feb 03	Buy	5.08	6,000	30,480	11,000	02/07/22
Ehrlich Christopher B	Director Director	Jan 27	Buy	5.303	5,000	26,515	5,000	01/31/22
ROOT JONATHAN D	Director Director	Dec 02	Sell	5.68	8,113	46,082	140,261	12/06/21
Presidio Management Group X LL...	10% Owner 10% Owner	Dec 02	Sell	5.68	8,113	46,082	140,261	12/06/21
Presidio Management Group X LL...	10% Owner 10% Owner	Nov 29	Sell	6.55	72,418	474,338	140,513	12/01/21
ROOT JONATHAN D	Director Director	Nov 29	Sell	6.55	72,418	474,338	140,513	12/01/21
ROOT JONATHAN D	Director Director	Nov 15	Sell	9.45	23,625	223,256	146,063	11/17/21
Presidio Management Group X LL...	10% Owner 10% Owner	Nov 15	Sell	9.45	23,625	223,256	146,063	11/17/21
ROOT JONATHAN D	Director Director	Nov 09	Sell	10.47	86,802	908,817	146,794	11/12/21
Presidio Management Group X LL...	10% Owner 10% Owner	Nov 09	Sell	10.47	86,802	908,817	146,794	11/12/21